Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

284.60 +42.65 (+17.63%)
Official Closing Price Updated: 7:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Bio-Rad Laboratories: Q4 Earnings Insights
 
Via Benzinga
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Preview: Bio-Rad Laboratories's Earnings
 
Via Benzinga
Earnings Outlook For Bio-Rad Laboratories
 
Via Benzinga
Bio-Rad Laboratories Inc. (NYSE: BIO) is a Leading Gainer in Wednesday Morning Trading
Via Investor Brand Network
The Latest Analyst Ratings for Bio-Rad Laboratories
 
Via Benzinga
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
10 S&P 500 Stocks With Over 40% Upside Potential: Hidden Gems Or Value Traps?
S&P 500 index surges to new highs, driven by AI, earnings optimism, and Fed rate cuts. Top 10 stocks with significant upside potential for 2024 rally. 
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
The Latest Analyst Ratings for Bio-Rad Laboratories
 
Via Benzinga
Death Cross Looms Over Bio-Rad Laboratories Investors
 
Via Benzinga
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations
Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential upside, but caution is needed. 
Via Benzinga
Topics Stocks
Why Is Clinical Diagnostic-Focused Bio-Rad Stock Trading Lower Today?
Bio-Rad Laboratories Inc (NYSE: BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the  
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Bio-Rad Reports Third-Quarter 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs. 
Via InvestorPlace
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Second-Quarter 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Why Are velo Biosciences Stock Is Trading Higher Today?
Evelo Biosciences Inc (NASDAQ: EVLO) shares are trading higher after the company terminated its sublease agreement with Bio-Rad Laboratories Inc (NYSE: BIO). 
Via Benzinga
Bio-Rad Announces New Share Repurchase Program
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Publishes Corporate Sustainability Report for 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
 
Via Benzinga
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.